JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

Dysregulation of Janus kinase (JAK)–signal transducer and activator of transcription signaling is central to the pathogenesis of myelofibrosis (MF). JAK2 inhibitor therapy in MF patients results in a rapid reduction of the degree of splenomegaly, yet the mechanism underlying this effect remains unkn...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Wang, Xiaoli, Ye, Fei, Tripodi, Joseph, Hu, Cing Siang, Qiu, Jiajing, Najfeld, Vesna, Novak, Jesse, Li, Yan, Rampal, Raajit, Hoffman, Ronald
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Myeloid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4224194/
https://ncbi.nlm.nih.gov/pubmed/25193869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558015
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items